Diamedica Inc (DMCAF) 0.0795 $DMCAF
DiaMedica to Present at the 17th Annual GCFF Conference in Toronto
Marketwired - Thu Sep 24, 7:02AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF), today announced that Rick Pauls, President and CEO, is scheduled to present at the upcoming 17th Annual Global Chinese Financial Forum (GCFF) Conference on Saturday September 26, 2015 at 2:55pm ET. The 2015 GCFF Conference will be held in Toronto, Courtyard by Marriott, Toronto Northeast/Markham.
DMA.VN: 0.100 (unch)
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 7.00 (+0.02), CNAT: 4.21 (-0.06), CLDN: 1.12 (+0.03), LLY: 86.14 (+2.37), CLSN: 1.84 (+0.14), ASND: 17.24 (+0.05), ABBV: 55.64 (-0.40), ANAC: 115.06 (+2.13), ARNA: 2.19 (+0.14)
DiaMedica Announces Listing on OTCQB Exchange
Marketwired - Thu Jul 16, 7:37AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company"
, announces that it has been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "DMCAF".
DMA.VN: 0.100 (unch)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Featuring 90+ Companies
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5gpct9/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 93 Companies Featured - 4SC AG - ActogeniX NV - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - American Gene Technologies International Inc. - AntriaBio, Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Axxam SpA - Bayhill Therapeutics, Inc. - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Cortendo AB - CTI BioPharma Corp. - Daewoong Pharmaceutical Co., Ltd. - Diabetology Limited - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A For more information visit http://www.researchandmarkets.com/research/5g...1_diabetes
AMBX: (), CTIC: 1.63 (-0.01), BIOD: 0.43 (+0.02), ARGS: 5.80 (-0.18), AZN: 32.23 (-0.16), CGEN: 5.68 (-0.02)
DiaMedica Completes Non-Brokered Private Placement
Marketwired - Fri Jun 19, 2:01PM CDT
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA), announced today the closing of its previously announced non-brokered private placement raising total gross proceeds of $975,000 (the "private placement" . The proceeds will be used by DiaMedica to support development with DM199 for the treatment of stroke and vascular diseases and for other working capital purposes.
DMA.VN: 0.100 (unch)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 32.23 (-0.16)
DiaMedica Announces Non-Brokered Private Placement
Marketwired - Fri Jun 05, 12:21PM CDT
DiaMedica Inc. (the "Company" (TSX VENTURE: DMA), announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered private placement of up to 6,000,000 Units in the capital of the Company at an issue price of $0.10 per Unit for gross proceeds of up to $600,000 (the "Offering" . Each Unit will consist of one common share in the capital of the Company (each a "Common Share" and one-half Common Share purchase warrant (each "Warrant" , with each Warrant entitling the holder thereof to acquire a further one-half Common Share (a "Warrant Share" at an exercise price of $0.20 per Common Share on the date that is twelve months after the date of issuance (the "Warrant Expiry Date" . All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date.
DMA.VN: 0.100 (unch)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 3.11 (-0.01), GALT: 2.61 (-0.10), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CTIC: 1.63 (-0.01), CNCE: 20.87 (+0.62), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), CCXI: 6.45 (+0.02), ICPT: 181.90 (-8.81), ABBV: 55.64 (-0.40)
DiaMedica to Present at LD Micro Invitational
Marketwired - Wed May 27, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), announced that Mr. Rick Pauls, President and Chief Executive Officer, will make an overview presentation of the Company's strategic direction at the LD Micro Conference on Monday, June 1, 2015 at 10:30AM PDT / 1:30PM EDT at the Luxe Hotel in Los Angeles, California. Mr. Pauls will also be available to participate in one-on-one meetings, made by appointment, with investors who are registered to attend the conference.
DMA.VN: 0.100 (unch)
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 269.16 (-10.72), ACOR: 29.89 (-0.22), GSK: 40.22 (+0.06), AZN: 32.23 (-0.16), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03)
DiaMedica to Present at the 12th Annual BIO Asia International Conference
Marketwired - Thu Mar 19, 9:20AM CDT
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the Company has been selected to present at the 12th Annual BIO Asia International Conference on March 24th, 2015 at 4:30 PM JST (UTC+9) at the Grand Hyatt Hotel in Tokyo, Japan. DiaMedica will be providing an overview of the expanded focus of DM199, a naturally occurring form of tissue kallikrein-1, into acute vascular diseases with an initial focus on acute ischemic stroke.
DMA.VN: 0.100 (unch)
DiaMedica to Present at the 17th Annual GCFF Conference in Toronto
Marketwired - Thu Sep 24, 7:02AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF), today announced that Rick Pauls, President and CEO, is scheduled to present at the upcoming 17th Annual Global Chinese Financial Forum (GCFF) Conference on Saturday September 26, 2015 at 2:55pm ET. The 2015 GCFF Conference will be held in Toronto, Courtyard by Marriott, Toronto Northeast/Markham.
DMA.VN: 0.100 (unch)
Hypertension - Pipeline Review, H1 2015 - Reviews Key Players Involved in the Therapeutics Development for Hypertension
M2 - Fri Aug 14, 8:34AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gn56xn/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Scope - The report provides a snapshot of the global therapeutic landscape of Hypertension - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report summarizes all the dormant and discontinued pipeline projects Key Topics Covered: - Introduction - Hypertension Overview - Therapeutics Development - Hypertension - Therapeutics under Development by Companies - Hypertension - Therapeutics under Investigation by Universities/Institutes - Hypertension - Pipeline Products Glance - Hypertension - Products under Development by Companies - Hypertension - Products under Investigation by Universities/Institutes - Hypertension - Companies Involved in Therapeutics Development - Hypertension - Therapeutics Assessment - Drug Profiles - Hypertension - Recent Pipeline Updates - Hypertension - Dormant Projects - Hypertension - Discontinued Products - Hypertension - Product Development Milestones Companies Mentioned - A1M Pharma AB - AbbVie Inc. - Ache Laboratorios Farmaceuticos S/A - Actelion Ltd - Ahn-Gook Pharmaceutical Co., Ltd. - Alnylam Pharmaceuticals, Inc. - Anacor Pharmaceuticals, Inc. - Angion Biomedica Corp. - APT Therapeutics, Inc. - Arena Pharmaceuticals, Inc. - Asahi Kasei Pharma Corp. - Ascendis Pharma A/S - Bayer AG - Bial - Portela & Ca, S.A. - Bio-inRen - Biocon Limited - Biolab Sanus Farmaceutica Ltda. - BioLineRx, Ltd. - Cardioxyl Pharmaceuticals, Inc. - Carolus Therapeutics, Inc. - Celladon Corporation - Cellceutix Corporation - Celsion Corporation - Chong Kun Dang Pharmaceutical Corp. - CJ CheilJedang Corp. - Conatus Pharmaceuticals Inc. - Corridor Pharmaceuticals Inc. - Cytokinetics, Inc. - Daewoong Pharmaceutical Co., Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dong-A Socio Group - Eli Lilly and Company For more information visit http://www.researchandmarkets.com/research/gn...pertension
CYTK: 7.00 (+0.02), CNAT: 4.21 (-0.06), CLDN: 1.12 (+0.03), LLY: 86.14 (+2.37), CLSN: 1.84 (+0.14), ASND: 17.24 (+0.05), ABBV: 55.64 (-0.40), ANAC: 115.06 (+2.13), ARNA: 2.19 (+0.14)
DiaMedica Announces Listing on OTCQB Exchange
Marketwired - Thu Jul 16, 7:37AM CDT
DiaMedica Inc. (TSX VENTURE: DMA)(OTCQB: DMCAF) (the "Company"
, announces that it has been listed for trading on the OTCQB(R) Market exchange in the United States under the symbol "DMCAF". DMA.VN: 0.100 (unch)
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015 Featuring 90+ Companies
M2 - Thu Jun 25, 6:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5gpct9/type_1_diabetes) has announced the addition of the "Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - 30 of the 93 Companies Featured - 4SC AG - ActogeniX NV - Adocia - AiCuris GmbH & Co. KG - Amarantus Bioscience Holdings, Inc. - Ambrx, Inc. - American Gene Technologies International Inc. - AntriaBio, Inc. - Argos Therapeutics, Inc. - Artery Therapeutics, Inc. - AstraZeneca PLC - Axxam SpA - Bayhill Therapeutics, Inc. - Beta-Cell NV - Biocon Limited - Biodel Inc. - Biogenomics Limited - BioLineRx, Ltd. - BioTherapeutics Inc. - Boehringer Ingelheim GmbH - Carlina Technologies SAS - Cellectis S.A. - Compugen Ltd. - Cortendo AB - CTI BioPharma Corp. - Daewoong Pharmaceutical Co., Ltd. - Diabetology Limited - DiaMedica Inc. - Diasome Pharmaceuticals, Inc. - Dompe Farmaceutici S.p.A For more information visit http://www.researchandmarkets.com/research/5g...1_diabetes
AMBX: (), CTIC: 1.63 (-0.01), BIOD: 0.43 (+0.02), ARGS: 5.80 (-0.18), AZN: 32.23 (-0.16), CGEN: 5.68 (-0.02)
DiaMedica Completes Non-Brokered Private Placement
Marketwired - Fri Jun 19, 2:01PM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA), announced today the closing of its previously announced non-brokered private placement raising total gross proceeds of $975,000 (the "private placement" . The proceeds will be used by DiaMedica to support development with DM199 for the treatment of stroke and vascular diseases and for other working capital purposes. DMA.VN: 0.100 (unch)
Acute Ischemic Stroke Pipeline Review, H1 2015 - 17 Companies & 22 Drug Profiles
M2 - Wed Jun 10, 5:00AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r894dh/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - AstraZeneca PLC - Biogen, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - Glucox Biotech AB - Grifols, S.A. - Lumosa Therapeutics Co., Ltd. - Mitsubishi Tanabe Pharma Corporation - Pharmicell Co., Ltd. - PhytoHealth Corporation - Remedy Pharmaceuticals, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. Drug Profiles - 3K3A-APC - Cerecellgram-Stroke - DB-017 - DM-199 - DS-1040 - glyburide - GM-602 - HBN-1 - Human Plasmin - LT-3001 - masitinib - Mesenchymal Stem Cells - MP-124 - natalizumab - Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke - PHN-014 - Recombinant Plasmin - SIM-071201 - Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke - Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke - THR-18 - ticagrelor For more information visit http://www.researchandmarkets.com/research/r8...e_ischemic
AZN: 32.23 (-0.16)
DiaMedica Announces Non-Brokered Private Placement
Marketwired - Fri Jun 05, 12:21PM CDT
DiaMedica Inc. (the "Company"
(TSX VENTURE: DMA), announces that, subject to TSX Venture Exchange approval, it is undertaking a non-brokered private placement of up to 6,000,000 Units in the capital of the Company at an issue price of $0.10 per Unit for gross proceeds of up to $600,000 (the "Offering" . Each Unit will consist of one common share in the capital of the Company (each a "Common Share" and one-half Common Share purchase warrant (each "Warrant" , with each Warrant entitling the holder thereof to acquire a further one-half Common Share (a "Warrant Share" at an exercise price of $0.20 per Common Share on the date that is twelve months after the date of issuance (the "Warrant Expiry Date" . All of the Units issued in connection with the Offering will be subject to a restricted period that expires four months after the issuance date. DMA.VN: 0.100 (unch)
Global Diabetic Nephropathy Pipeline Review, H1 2015
M2 - Tue Jun 02, 7:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/frxw7k/diabetic) has announced the addition of the "Diabetic Nephropathy - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diabetic Nephropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diabetic Nephropathy and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Aerpio Therapeutics, Inc. - Antisense Therapeutics Limited - Astellas Pharma Inc. - AstraZeneca PLC - Bayer AG - Bristol-Myers Squibb Company - Cellmid Limited - ChemoCentryx, Inc. - Concert Pharmaceuticals, Inc. - CTI BioPharma Corp. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Dimerix Bioscience Pty Ltd - Dong Wha Pharma Co., Ltd. - Eli Lilly and Company - Galectin Therapeutics, Inc. - GenKyoTex S.A. - Gentium S.p.A. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Glucox Biotech AB - GNI Group Ltd. - IMMD Inc. - Intercept Pharmaceuticals, Inc. - InterMune, Inc. - Inventiva SAS - Islet Sciences, Inc. - Jenrin Discovery, Inc. - Johnson & Johnson - Mallinckrodt plc - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - NephroGenex, Inc. - Noxxon Pharma AG For more information visit http://www.researchandmarkets.com/research/frxw7k/diabetic
NRX: 3.11 (-0.01), GALT: 2.61 (-0.10), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), BMY: 61.44 (+0.93), CTIC: 1.63 (-0.01), CNCE: 20.87 (+0.62), JNJ: 95.37 (+0.29), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), CCXI: 6.45 (+0.02), ICPT: 181.90 (-8.81), ABBV: 55.64 (-0.40)
DiaMedica to Present at LD Micro Invitational
Marketwired - Wed May 27, 7:03AM CDT
DiaMedica Inc. (TSX VENTURE: DMA), announced that Mr. Rick Pauls, President and Chief Executive Officer, will make an overview presentation of the Company's strategic direction at the LD Micro Conference on Monday, June 1, 2015 at 10:30AM PDT / 1:30PM EDT at the Luxe Hotel in Los Angeles, California. Mr. Pauls will also be available to participate in one-on-one meetings, made by appointment, with investors who are registered to attend the conference.
DMA.VN: 0.100 (unch)
Avivagen Announces Two Appointments to its Board of Directors, Mr. David Allan and Ms. Vanessa Grant
ACCESSWIRE - Thu May 14, 6:34AM CDT
OTTAWA, ON/ ACCESSWIRE / May 14 2015 / Avivagen Inc. (TSXV:VIV, PINKSHEETS:CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces the appointment of two new Directors, Mr. David Allan and Ms. Vanessa Grant, and the resignation of two past Directors, Dr. Janusz Daroszewski and Dr. Chandra Panchal.
Global Ischemic Stroke Pipeline Report 2015
M2 - Thu May 14, 5:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/w6cj3m/ischemic_stroke) has announced the addition of the "Ischemic Stroke - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemic Stroke and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AB Science - Acorda Therapeutics, Inc. - Acticor Biotech - advanceCor GmbH - AGY Therapeutics, Inc. - Angion Biomedica Corp. - AstraZeneca PLC - Athersys, Inc. - Biogen Idec Inc. - BioTime, Inc. - D-Pharm Ltd. - Daiichi Sankyo Company, Limited - DiaMedica Inc. - Digna Biotech, S.L. - Genervon Biopharmaceuticals, LLC - GlaxoSmithKline plc - International Stem Cell Corporation - Laboratoires Pierre Fabre SA - Lumosa Therapeutics Co., Ltd. - MediaPharma s.r.l. - Mesoblast Limited - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neurotec Pharma SL - NeuroVive Pharmaceutical AB - Panacea Pharmaceuticals, Inc. - Pharmicell Co., Ltd. - PhytoHealth Corporation - SanBio, Inc. - Saneron CCEL Therapeutics, Inc. - Simcere Pharmaceutical Group - Stemedica Cell Technologies, Inc. - Vicore Pharma AB - Virogenomics, Inc. For more information visit http://www.researchandmarkets.com/research/w6...mic_stroke
BIIB: 269.16 (-10.72), ACOR: 29.89 (-0.22), GSK: 40.22 (+0.06), AZN: 32.23 (-0.16), ATHX: 1.14 (-0.01), CUR: 1.33 (+0.03)
DiaMedica to Present at the 12th Annual BIO Asia International Conference
Marketwired - Thu Mar 19, 9:20AM CDT
DiaMedica Inc. (TSX VENTURE: DMA) today, announced that the Company has been selected to present at the 12th Annual BIO Asia International Conference on March 24th, 2015 at 4:30 PM JST (UTC+9) at the Grand Hyatt Hotel in Tokyo, Japan. DiaMedica will be providing an overview of the expanded focus of DM199, a naturally occurring form of tissue kallikrein-1, into acute vascular diseases with an initial focus on acute ischemic stroke.
DMA.VN: 0.100 (unch)
